Trial NCT02624986

View at ClinicalTrials.gov 
Org. Study IDs: BH29812
Secondary IDs: 2015-002100-83

Last trial update was posted on 2020-05-18

MeSH Interventions

Obinutuzumab Rituximab

MeSH Conditions

Lymphoma Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse

Other Conditions

Non-Hodgkin's Lymphoma

Stopping Reasons

Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.

Limitations And Caveats

Due to the overall modest benefit achieved with the maximum tolerated dose during the dose escalation phase, the Sponsor decided not to open the expansion phase and terminated the study. Consequently, some planned analyses could not be performed.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID